Recombinant Human SAT2 protein

中文名： 精脒/精胺N1乙酰基转移酶2(SAT2)重组蛋白
别名： SAT2;SSAT2;Thialysine N-epsilon-acetyltransferase

货号: PA1000-2840

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	SAT2
Uniprot No	Q502X4
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-190aa
氨基酸序列	MGSSHHHHHH SSGLVPRGSH MASVRIREAK EGDCGDILRL IRELAEFEKL SDQVKISEEA LRADGFGDNP FYHCLVAEIL PAPGKLLGPC VVGYGIYYFI YSTWKGRTIY LEDIYVMPEY RGQGIGSKII KKVAEVALDK GCSQFRLAVL DWNQRAMDLY KALGAQDLTE AEGWHFFCFQ GEATRKLAGK
预测分子量	21 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于SAT2重组蛋白的3篇代表性文献(部分信息为模拟示例)：

1. **文献名称**：Development of a Recombinant SAT2 Foot-and-Mouth Disease Virus Antigen for Serological Diagnosis

**作者**：Smith J, et al.

**摘要**：研究利用昆虫细胞表达系统制备SAT2型口蹄疫病毒(FMDV)重组VP1蛋白，证明其可用于ELISA检测，具有高灵敏度和特异性，适用于SAT2抗体筛查。

2. **文献名称**：Expression and Immunogenicity of SAT2 FMDV Structural Proteins in a Baculovirus System

**作者**：Wang L, et al.

**摘要**：通过杆状病毒系统共表达SAT2的VP0、VP1和VP3蛋白，形成病毒样颗粒(VLPs)，动物实验显示其诱导中和抗体，为新型疫苗研发提供基础。

3. **文献名称**：Chimeric SAT2 Foot-and-Mouth Disease Virus Capsid Proteins Enhance Cross-Protective Immunity

**作者**：Maree FF, et al.

**摘要**：构建SAT2与O型FMDV的嵌合重组衣壳蛋白，证明其可拓宽疫苗免疫覆盖范围，解决SAT2血清型内抗原变异导致的免疫保护局限问题。

---

**说明**：

- 以上文献为示例，实际研究中建议通过PubMed或Web of Science以“SAT2 recombinant protein”“FMDV SAT2 vaccine”等关键词检索最新论文。

- 重点关注期刊：*Vaccine*、*Virology*、*Archives of Virology*。

- 部分SAT2重组蛋白研究团队：OIE参考实验室(如中国兰州兽医研究所、南非Onderstepoort研究所)。

背景信息

**Background of SAT2 Recombinant Proteins**

SAT2 (Southern African Territories 2) is one of the seven serotypes of foot-and-mouth disease virus (FMDV), a highly contagious pathogen affecting cloven-hoofed animals. SAT2 is endemic in parts of Africa and Asia, posing significant economic risks due to trade restrictions and livestock losses. Traditional inactivated vaccines for FMDV face challenges, including antigenic variability among subtypes, limited cross-protection, and biosafety concerns during production.

Recombinant protein technology offers a promising alternative. SAT2 recombinant proteins, typically expressed in systems like *E. coli*, yeast, or mammalian cells, focus on antigenic viral components such as VP1 structural proteins or virus-like particles (VLPs). These proteins mimic natural antigens but eliminate infectious risks. For instance, VP1 contains critical epitopes that induce neutralizing antibodies, while VLPs preserve conformational antigenic sites, enhancing immune recognition.

Research on SAT2 recombinant vaccines aims to address antigenic mismatch between vaccines and circulating strains, a common issue due to the virus’s high mutation rate. By incorporating multiple epitopes or chimeric designs, recombinant proteins can broaden protection across SAT2 variants. Additionally, these proteins serve as diagnostic tools, enabling serotype-specific antibody detection without live virus handling.

Despite progress, challenges remain. Achieving optimal immunogenicity, scaling production cost-effectively, and ensuring long-term stability require further optimization. Advances in bioengineering and adjuvant systems continue to refine SAT2 recombinant protein applications, supporting global efforts toward safer, adaptable FMD control strategies.